02508nas a2200313   4500000000100000008004100001260001200042100001700054700002000071700002100091700001700112700001800129700001900147700001900166700002100185700001700206700003100223700001400254700001700268700001900285700002900304700001600333700002200349700001800371245006500389856005400454300001200508520167400520       2021                            d  c2021-041 aRachel Abudu1 aGauthier Bouche1 aKarima Bourougaa1 aLynne Davies1 aKalina Duncan1 aCarla Estaquio1 aAnna Diaz Font1 aMarc S. Hurlbert1 aPaul Jackson1 aLinda Kroeskop-Bossenbroek1 aIan Lewis1 aGiota Mitrou1 aAbdul Mutabbir1 aChristopher A. Pettigrew1 aLynn Turner1 aAnnemarie Weerman1 aKari Wojtanik00aTrends in International Cancer Research Investment 2006-2018  uhttps://ascopubs.org/doi/full/10.1200/GO.20.00591  a602-6103 aThe International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.